N
ZNTL icon

Nuveen’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Nuveen’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-507,527
Closed -$807K – 3426
2025
Q1 		$807K Sell
507,527
-133,880
-21% -$289K ﹤0.01% 2734
2024
Q4 		$1.94M Buy
641,407
+167,062
+35% +$547K ﹤0.01% 2401
2024
Q3 		$1.75M Buy
474,345
+344,037
+264% +$1.25M ﹤0.01% 2486
2024
Q2 		$533K Hold
130,308
– – ﹤0.01% 2966
2024
Q1 		$2.05M Hold
130,308
– – ﹤0.01% 2389
2023
Q4 		$1.97M Buy
130,308
+2,138
+2% +$31.2K ﹤0.01% 2415
2023
Q3 		$2.57M Buy
128,170
+10,774
+9% +$273K ﹤0.01% 2195
2023
Q2 		$3.31M Buy
117,396
+2,885
+3% +$69.2K ﹤0.01% 2112
2023
Q1 		$1.97M Sell
114,511
-1,559
-1% -$31.6K ﹤0.01% 2337
2022
Q4 		$2.34M Sell
116,070
-7,496
-6% -$161K ﹤0.01% 2311
2022
Q3 		$2.68M Buy
123,566
+11,239
+10% +$307K ﹤0.01% 2243
2022
Q2 		$3.16M Sell
112,327
-5,995
-5% -$159K ﹤0.01% 2205
2022
Q1 		$5.79M Sell
118,322
-2,334
-2% -$126K ﹤0.01% 1977
2021
Q4 		$8.6M Sell
120,656
-8,383
-6% -$649K ﹤0.01% 1788
2021
Q3 		$9.07M Sell
129,039
-7,560
-6% -$436K ﹤0.01% 1845
2021
Q2 		$7.27M Buy
136,599
+19,699
+17% +$1.06M ﹤0.01% 2058
2021
Q1 		$5.07M Buy
116,900
+10,908
+10% +$470K ﹤0.01% 2166
2020
Q4 		$5.5M Buy
105,992
+65,359
+161% +$2.95M ﹤0.01% 2022
2020
Q3 		$1.33M Buy
40,633
+169
+0.4% +$5.92K ﹤0.01% 2563
2020
Q2 		$1.94M Buy
+40,464
New +$1.55M ﹤0.01% 2350

Other funds holding ZNTL

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return

Nuveen's ZNTL Position: Q2 2025 in Review

Nuveen sold out of Zentalis Pharmaceuticals (ZNTL) in Q2 2025, closing a stake of 507,527 shares — an estimated $807K sold.

Nuveen first reported a position in ZNTL in Q2 2020 and held it in 20 quarters. The position peaked at $9.07M in Q3 2021. 117 funds tracked by Wall St. Rank hold ZNTL as of Q2 2025.

  • Nuveen reported no remaining Zentalis Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Nuveen sold 507,527 Zentalis Pharmaceuticals shares in Q2 2025, an estimated $807K.
  • Nuveen first reported a position in Zentalis Pharmaceuticals in Q2 2020 and held it in 20 quarters.
  • Nuveen's Zentalis Pharmaceuticals position peaked at $9.07M in Q3 2021.
  • 117 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2025.

Based on Nuveen's 13F filing for Q2 2025, filed 12 Aug 2025.